In summary, because glycolysis and VM formation are prevalently dysregulated in cancers, therapeutic interventions based on the SOX2-lncRNA AC005392.2-GLUT1 axis may be promising in the treatment of CRC patients. The gene discussed is SLC2A1; the disease is cancer.